KORU Medical Systems (NASDAQ:KRMD) Price Target Raised to $3.50 at Piper Sandler

KORU Medical Systems (NASDAQ:KRMD) had its price objective upped by Piper Sandler from $3.00 to $3.50 in a report published on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Separately, B. Riley initiated coverage on shares of KORU Medical Systems in a research report on Thursday, July 25th. They issued a “buy” rating and a $4.00 price target for the company.

KORU Medical Systems Trading Up 2.9 %

Shares of KORU Medical Systems stock opened at $3.17 on Thursday. The company has a current ratio of 2.99, a quick ratio of 3.27 and a debt-to-equity ratio of 0.01. KORU Medical Systems has a twelve month low of $1.98 and a twelve month high of $3.40. The company has a 50-day simple moving average of $2.67 and a two-hundred day simple moving average of $2.48.

Institutional Investors Weigh In On KORU Medical Systems

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in KORU Medical Systems by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,961,764 shares of the company’s stock valued at $4,630,000 after buying an additional 51,890 shares during the period. Aaron Wealth Advisors LLC acquired a new stake in shares of KORU Medical Systems during the 2nd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in KORU Medical Systems in the second quarter valued at approximately $107,000. Legato Capital Management LLC acquired a new position in KORU Medical Systems during the second quarter valued at approximately $35,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in KORU Medical Systems during the second quarter worth $28,000. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.